NSE · MOREPENLAB
Morepen Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹463 Cr with net profit ₹20 Cr — a 4.35% net margin, versus 5.14% the period before.
Shareholding
As of 2026-06-30
- Promoter35.65%
- Public61.6%
- FII1.46%
- DII1.28%
4,34,912 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.95× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #40 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,73,629 Cr | 38.11 | 5.67 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,20,143 Cr | 216.48 | 3.49 | 11.27% | 14% |
| Lupin Limited | ₹1,12,127 Cr | 70.41 | 4.99 | 23.76% | 19.4% |
| Zydus Lifesciences Ltd. | ₹1,12,000 Cr | 20.62 | 4.13 | 18.59% | 18.86% |
| Mankind Pharma Limited | ₹1,08,077 Cr | 194.71 | 6.63 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,478 Cr | 345.42 | 18.19 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,369 Cr | 431.17 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,231 Cr | 100.13 | 2.43 | 9.25% | 10.5% |
| Biocon Ltd. | ₹70,007 Cr | 546.71 | 2.06 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹68,056 Cr | 287.91 | 4.92 | 16.66% | 15.65% |
| Morepen Laboratories Ltd.(this company) | ₹3,104 Cr | 202.32 | 2.49 | 5.96% | 5.25% |
AI analysis
AI-generated · google/gemini-2.5-flashMorepen Laboratories Ltd. is listed with a market capitalization of Rs 3110 Cr. The company reported annual revenue of Rs 1829.94 Cr and an EPS of 1.85. Its debt-to-equity ratio stands at 0.06.
Positives
- +The company's debt-to-equity ratio is low at 0.06.
- +No shares were pledged by promoters as of June 30, 2026.
- +Annual revenue for March 2025 was Rs 1829.94 Cr.
Negatives
- −Promoter holding decreased from 35.6548% in June 2026 to no data available for earlier periods, preventing a clear trend analysis.
- −The quarterly net profit in March 2026 was Rs 15.74 Cr, a decrease from Rs 27.51 Cr in December 2025.
- −The return on capital employed (ROCE) is 7.58%, which is relatively low.
- −The company has not disclosed quarterly results since March 2026, affecting up-to-date performance assessment.
Financial performance
Morepen Laboratories Ltd. reported annual revenue of Rs 1829.94 Cr for the period ending March 2025. The company's net profit for the same period was Rs 118.02 Cr, resulting in an EPS of 2.2. Quarterly revenues have varied, with Rs 484.72 Cr in March 2026 and Rs 411.58 Cr in September 2025.
Profitability & returns
The company's return on equity (ROE) is 9.8%, and its return on capital employed (ROCE) is 7.58%. For the year ending March 2025, EBITDA was Rs 163.45 Cr, while net profit was Rs 118.02 Cr. Quarterly EBITDA figures show a range from Rs 19.55 Cr in June 2025 to Rs 39.74 Cr in December 2025.
Balance sheet
Morepen Laboratories Ltd. has a low debt-to-equity ratio of 0.06, indicating limited reliance on borrowed capital. The book value per share is Rs 21.56. The company's market capitalization is Rs 3110 Cr.
Ownership & pledges
As of June 30, 2026, promoters held 35.65% of the company's shares. Public shareholding was 61.60%, while institutional holdings (DII and FII combined) accounted for 2.74%. There were no promoter shares reported as pledged.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.